Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 22nd Preview)
-
Immuno-oncology – China regulatory filing for a novel 4-1BB bispecific
China’s NMPA accepted the NDA for opamtistomig (LBL-024), a PD-L1/4-1BB–directed bispecific antibody, for previously treated advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The Center for Drug Evaluation granted priority review on July 10, 2026, with the regulatory decision expected to follow the next stage of the filing process. The submission is supported by a registrational study led by Lin Shen, MD, of Peking University Cancer Hospital. Enrollment was completed for 96 patients across 34 sites in August 2025. Previously reported results cited in the filing show an objective response rate of 33.3% in EP-NEC. If approved, opamtistomig would mark the first marketed therapy directly targeting 4-1BB and the first approved agonistic antibody against the costimulatory receptor in the setting described. The company positions the mechanism as combining PD-L1 immune suppression blockade with conditional 4-1BB agonist signaling aimed at reactivating exhausted T cells. The NDA also builds on broader development activity for opamtistomig across solid tumor indications in China, including one pivotal registration trial and multiple proof-of-concept studies, with detailed data slated for presentation at an international meeting.
-
Oncology – early-stage antibody signal in pre-surgery HER2-positive breast cancer
Zanidatamab is showing early promise in a pre-surgical setting for HER2-positive breast cancer, with results from the NeoZanHER phase 2 trial reported in Nature Communications. The study evaluates the next-generation HER2 antibody in early-stage disease, targeting patients before surgery to assess tumor response and translational biomarkers. The trial was led by the study group cited in the report and designed around the concept that neoadjuvant therapy can reveal efficacy signals faster than a purely post-surgical approach. The Nature Communications publication focuses on clinical activity in the neoadjuvant window rather than late endpoints. For HER2-directed development, the key operational takeaway is the continued expansion of bispecific-leaning HER2 formats into earlier lines and earlier decision points, including trials where response rates can guide whether programs move toward larger confirmatory studies. As with other neoadjuvant antibody strategies, the regulatory and commercial implications hinge on pathologic response measures, duration of activity, and safety in a population that may also be receiving standard chemotherapy and anti-HER2 backbone therapies.
-
Rare disease & RNA interference – Phase II efficacy for divesiran in polycythemia vera
Silence Therapeutics reported positive Phase II results for divesiran, an siRNA designed for polycythemia vera (PV), a rare blood cancer with burdensome phlebotomy requirements. In the SANRECO trial (NCT05499013), divesiran met its primary endpoint with an 88% response rate versus 19% in placebo-controlled groups. Company commentary in the report attributes the efficacy to TMPRSS6 silencing, a gene regulators use to control iron balance and red blood cell production. The program’s clinical framing centers on steadier hematocrit control—measured as percent of red blood cells—while reducing how often patients need phlebotomy. The release also highlights durability in trial follow-up, including a reported total of 36 weeks without requiring phlebotomy for patients on divesiran and dosing intervals as infrequent as every three months. The company links hematocrit control to lower risk of thrombotic events, a major driver of morbidity and mortality in PV. Operationally, the results support moving toward later-stage evaluation of an siRNA approach in PV where the standard-of-care remains driven largely by phlebotomy and symptom management. If the signal holds up in larger studies, divesiran could challenge current hematocrit management paradigms with longer dosing intervals and mechanism-based control.
-
Drug safety – real-world psychosis signal for subcutaneous foslevodopa/foscarbidopa
A retrospective real-world study is drawing attention to psychotic complications seen during use of subcutaneous foslevodopa/foscarbidopa infusions in Parkinson’s disease. Researchers examined 198 patients and focused on episodes involving hallucinations, delusions and related disturbances. The dataset is observational and retrospective, but its clinical value is in capturing adverse-event patterns under routine conditions outside tightly controlled trials. The findings help inform prescriber monitoring and patient counseling for infusion-based levodopa delivery formats that aim to smooth motor fluctuations. As such delivery technologies move deeper into clinical practice, identifying and characterizing the risk profile—including the frequency, timing, and potential patient factors associated with psychiatric events—becomes part of the pathway to broader adoption. For clinicians, the practical implication is tighter vigilance for psychotic symptoms after initiation and during dose adjustments, especially in patients with known vulnerability to hallucinations or those receiving other neuropsychiatric-active therapies.
-
Neurodegeneration – targeted alpha-synuclein degradation blocks PFF aggregation
A study in npj Parkinson’s Disease reports that selectively degrading alpha-synuclein can block aggregation triggered by preformed fibrils (PFFs). Researchers describe a targeted protein degradation strategy designed to reduce the availability of alpha-synuclein species required for misfolding and accumulation. The work’s mechanistic focus is on aggregation biology—one of the central hypotheses in synucleinopathies—and it frames the approach as a way to prevent the protein from forming toxic aggregates rather than merely inhibiting upstream pathways. By showing blockade of PFF-induced aggregation, the findings provide preclinical support for degradation-based therapies in Parkinson’s disease, where multiple modalities are under investigation including antibodies, small molecules, and gene-silencing approaches. For drug developers, degradation carries a distinct translational profile: it can create a more durable reduction in target levels, but it also requires careful assessment of safety, brain penetration, and specificity across synuclein isoforms and related proteins in later studies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.